Amgen's strategic growth through M&A and R&D investments has led to a diversified portfolio. Find out why I give AMGN stock a ...

Biocon Biologics has received approval from the US Food and Drug Administration for the intravenous use of Jobevne ...

Biocon Biologics has received the Food and Drug Administration’s green light for Jobevne (bevacizumab-nwgd), a biosimilar ...

Biocon Biologics (BBL), a subsidiary of Biocon, today announced that the U.S. Food and Drug Administration (U.S. FDA) has approved Jobevne (bevacizumab-nwgd), a biosimilar Bevacizumab for intravenous ...

During a live event, Marc S. Hoffmann, MD, discussed outcomes from the SEQUOIA and ELEVATE-TN studies in chronic lymphocytic ...

Biocon’s share price rose 5.5% after USFDA approved JOBEVNE, a biosimilar cancer drug. This marks the company’s seventh USFDA ...

Biocon Biologics, a subsidiary of Biocon, has scored a major win with the U.S. FDA approving JOBEVNE (bevacizumab-nwgd), a biosimilar to Roche's blockbuster cancer drug Avastin.

In 2023, bevacizumab sales in the U.S. were around $2.0 billion. Biocon Biologics serves over 5 million patients each year ...

BRIDGEWATER, N.J. and BENGALURU, India, April 10, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the ...

Biocon Biologics Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved JOBEVNE™ (bevacizumab-nwgd), a ...

Biocon's stock price increased almost 4 per cent in the early trading session on 11 April after the company’s subsidiary ...